5th International HIV/Viral Hepatitis Co-Infection Meeting
Viral hepatitis elimination in Latin America and globally: How close are we?

20-21 July 2019 | Mexico City, Mexico

In July 2017, the IAS HIV Co-Infections and Co-Morbidities initiative hosted the 4th International HIV/Viral Hepatitis Co-Infection Meeting as a pre conference prior to IAS 2017. The meeting was themed “The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low- to high-income settings”. It brought together clinicians, researchers and advocates (including several from the community) seeking to address the challenges of achieving elimination of hepatitis B and C in people living with HIV worldwide. Building on the content from the meeting, the initiative published a JIAS supplement entitled “Towards global viral hepatitis elimination for all patients in all income settings”.

The 5th International HIV/Viral Hepatitis Co Infection Meeting will take place as a pre-conference prior to IAS 2019 in Mexico City, Mexico. Similarly to earlier editions, the meeting will provide a unique opportunity to bring together a diversity of scientific, technical and community interests to discuss current opportunities and challenges for increased prevention, diagnosis and treatment of viral hepatitis in people living with HIV (and other populations). The meeting will cover implementation challenges to achieving elimination of hepatitis B and C worldwide. This will include a focus on access to care for people living with HIV and other key and marginalized populations with overlapping risks for both HIV and viral hepatitis, such as people who inject drugs, prisoners, indigenous people, migrants and men who have sex with men. A session on HBV cure will take place in collaboration with the IAS HIV & HBV Cure Forum convened by the Towards an HIV Cure initiative. The programme will display a mixture of formats, including invited keynotes, debates and roundtables, as well as an abstract driven poster exhibition, which will help drive interest not only from people working in HIV, but also from people working primarily in the viral hepatitis field. In addition, a strong community participation will allow grounding the topics in real-life contexts and lived experiences.

The 5th International HIV/Viral Hepatitis Co-Infection Meeting will take place at:

Unidad De Congresos Centro Medico Nacional Siglo XXI IMSS
Avenida Cuauhtémoc 330, Doctores, 06720 Ciudad de México, CDMX

Please note that this is not the same venue as the IAS 2019 Conference, and so please take this into account when planning your travel to the meeting.

Registration

Online registration for this meeting is now closed. Onsite registration is possible on 20 July 2019, but will be on a first come first serve basis as capacity is limited. Onsite registration will be available at the following rates:

Low- and middle-income countries 75 EUR 85 USD 1,600 MXN
High-income countries 200 EUR 225 USD 4,300 MXN

Abstract submission

Abstracts submitted to IAS 2019 had the opportunity to be considered also for the 5th International HIV/Viral Hepatitis Co-Infection Meeting. Abstract submission is now closed.

Organizing committee

Co-chairs
Giten Khwairakpam, TREAT Asia, Bangkok, Thailand
Natalia Laufer, INBIRS Institute UBA-CONICET, Buenos Aires, Argentina
Luis Soto Ramirez*, Instituto Nacional de Ciencias Médicas y Nutricion Salvador Zubiran, Mexico City, Mexico

Members
Rakesh Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Monique Andersson, Stellenbosch University Cape Town, South Africa
Marc Bulterys, WHO Geneva, Switzerland
Hugo Cheinquer, Hospital de Clinicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Jordan Feld, University of Toronto, Toronto, Canada
Sergey Golovin, International Treatment Preparedness Coalition Eastern Europe and Central Asia, Saint Petersburg, Russia
Jason Grebely, Kirby Institute; International Network on Hepatitis in Substance Users, Sydney, Australia
Saeed Sadiq Hamid, Aga Khan University, Karachi, Pakistan
Margaret Hellard, Burnet Institute, Melbourne, Australia
Marina Klein*, McGill University; CIHR Canadian HIV Trials Network, Montreal, Canada
Karine Lacombe, Hôpital Saint-Antoine, Paris, France
Liudmyla Maistat, Medicines Patent Pool, Geneva, Switzerland
Dasha Matyushina-Ocheret, Eurasian Harm Reduction Association, Vilnius, Lithuania
Sébastien Morin, International AIDS Society, Geneva, Switzerland
Raquel Peck, World Hepatitis Alliance, London, UK
Chase Perfect, Coalition Plus, Paris, France
Jorge Quarleri, University of Buenos Aires, Buenos Aires, Argentina
Jürgen Rockstroh*, University of Bonn, Bonn, Germany
Andrew Scheibe, TB HIV Care, Cape Town, South Africa
Marcelo Oscar Silva, Hepatology and Liver Transplant Unit, Austral University Hospital, Buenos Aires, Argentina
Tracy Swan, Independent, New York, USA
Ernst Wisse, Médecins du Monde, Paris, France

* IAS Governing Council member

Meeting material

  • Related documents
  • Day 1
  • Day 2

Session 1 – Welcome and introduction: Progress towards HIV/HBV and HIV/HCV elimination

PAHO overview: Progress and barriers towards HBV and HCV elimination targets globally and in the Americas
Massimo Ghidinelli, Pan American Health Organisation, United States

Presentation | Video

Latin American perspective on HIV and viral hepatitis
Natalia Laufer, INBIRS Institute UBA-CONICET, Argentina

Presentation | Video

Implementation and access to medicines
Giten Khwairakpam, TREAT Asia, Thailand

Presentation | Video

Session 2 – Access to HBV care: Current status and remaining challenges

Expanding access to HBV birth dose vaccination
Monique Andersson, Stellenbosch University; Oxford University NHS Foundation Trust, United Kingdom

Presentation | Video

Ensuring access to HBV medicines in public and private markets
Leena Menghaney, Médecins Sans Frontiéres, India

Presentation N/A | Video

Financing the HBV response: Within and outside the context of HIV co-infection
María Eugenia de Feo Moyano, Universidad Nacional de La Plata, Argentina

Presentation | Video

Session 3 – Access to HCV care: Current status and remaining challenges

Improving HCV case finding: Where are the missing millions?
Cary James, World Hepatitis Alliance, United Kingdom

Presentation | Video

Scaling up HCV treatment and financing the HCV response: Within and outside the context of HIV co-infection
Margaret Hellard, Burnet Institute, Australia

Presentation N/A | Video N/A

Session 4 – Latin American community perspective: Social determinants of HBV and HCV risk for marginalized populations

People who inject drugs
Brun González, Espolea & INPUD, Mexico

Presentation | Video

Forced migrants
Carla Vizzotti, Venezuela

Presentation | Video

Discussion: Addressing community challenges in Latin America

  • Indigenous people: Noly Fernandez, Indigenous Health Department, Venezuela
  • Men who have sex with men: Sergio López, SOMOSGAY, Paraguay
  • Prisoners: Estela Carrizo, Argentina
  • Transgender people: Alexandra Rodríguez, El/La Para TransLatinas, Mexico

Presentation N/A |Video

Session 5 – HBV cure research: Presented by the IAS HIV & HBV Cure Forum

Challenges and approaches for virological cure
Jake Liang, NIH Intramural Research Program , United States

Presentation | Video

Challenges and approaches for immunological cures
Mala Maini, University College London, United Kingdom

Presentation | Video

Discussion

Presentation N/A | Video

Session 6 – Opportunities to address HBV and HCV

Addressing HBV and HCV in children and adolescents
Philippa Easterbrook, WHO, Switzerland

Presentation | Video

Technologies to support diagnosis and linkage to care: Knowing your status and getting care 2.0
Jilian Sacks, Clinton Health Access Initiative, United States

Presentation | Video

Scaling up injecting drug use harm reduction services: Working in the context of criminalization
Ernst Wisse, Médecins du Monde, France

Presentation | Video

Session 7 – Scale up: HCV micro elimination

Case study 1: Micro elimination in HIV/HCV patients
Maria Prins, Public Health Service of Amsterdam (GGD); Academic Medical Center, University of Amsterdam, Netherlands

Presentation | Video

Case study 2: Micro elimination in prisons and other closed settings
Nadine Kronfli, McGill University and CIHR Canadian HIV Trials Network, Canada

Presentation | Video

Case study 3: Micro elimination in networks of people who inject drugs
Julie Bruneau, Université de Montréal, Canada

Presentation | Video

Case study 4: Micro elimination in small geographical settings
Magnus Gottfredsson, Landspitali University Hospital, Iceland

Presentation | Video

Debate: HCV micro elimination is not possible
Cate Hankins, Amsterdam Institute for Global Health and Development, Canada
Andriy Klepikov, Alliance for Public Health, Ukraine
Margaret Hellard, Burnet Institute, Australia

Presentation | Video

Session 8 – Closing: Summary and call to action

The role of parliamentarians in removing legal barriers to and supporting HBV and HCV elimination efforts
Ricardo Baptista Leite, UNITE, Portugal

Presentation | Video

Meeting summary: Two days in review
Marina Klein, McGill University and CIHR Canadian HIV Trials Network, Canada

Presentation | Video

Call to action: What will it take to reach HBV and HCV elimination in Latin America?
Natalia Laufer, INBIRS Institute UBA-CONICET, Argentina

Presentation | Video

Donor

     
 

Endorsed by

       
 

For information on sponsorship opportunities, please contact [email protected].

Previous Meetings

4th International HIV/Viral Hepatitis Co-Infection Meeting
Read more

3rd International HIV/Viral Hepatitis Co-Infection Meeting
Read more